Personalized Immune Cell Therapy Targeting Neoantigen of Malignant Solid Tumors

NCT05235607 · clinicaltrials.gov ↗

PHASE1

Phase

UNKNOWN

Status

60

Enrollment

OTHER

Sponsor class

Conditions

Carcinoma
Melanoma
Bladder Cancer
Colorectal Cancer

Interventions

BIOLOGICAL: Tumor antigen-sensitized DC vaccine and their sensitized T cells subcutaneous administration

Sponsor

Sichuan University